Pocket Program - CROI

CROI 2013 Session 65
c Tuesday, 2:30-4 pm; Hall B2
Session 62–Poster Abstracts
Shutting the Door on HIV Entry
241
251
Joseph Casazza*, A Vostal, D Ambrozak, B Hill, E Boritz, I Gong,
Geoffrey Ferir*, K Palmer, and D Schols
D Douek, and R Koup
Rega Inst for Med Res, Univ of Leuven, Belgium
Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US
c Tuesday, 2:30-4 pm; Hall B2
Session 63–Poster Abstracts
(see Session 45 on Wednesday for corresponding Themed Discussion)
Transmitted/Founder Viruses
244
Infection in Individuals Infected with Multiple Transmitted/
Hongshuo Song* 1 , F Cai 1 , V Ganusov 2 , J Pavlicek 1 , B Keele 3 , H Li 4 ,
G Shaw 4 , B Haynes 1 , B Hahn 4 , and F Gao 1
1 Duke Univ Med Ctr, Durham, NC, US;; 2 Univ of Tennessee, Knoxville,
US;; 3 SAIC-Frederick Inc, MD, US;; and 4 Univ of Pennsylvania,
Philadelphia, US
245 MTCT Is Associated with a Gag-Protease-driven Viral
Vanessa Naidoo* 1 , J Mann 1 , J Carlson 2 , C Brumme 3 , C Thobakgale 1 ,
P Goulder 4 , D Heckerman 2 , Z Brumme 3,5 , M Brockman 3,5 , and T Ndung’u 1
1 HIV Pathogenesis Prgm, Univ of KwaZulu-Natal, Durban, South Africa;;
2 Microsoft Res, Los Angeles, CA, US;; 3 BC Ctr for Excellence in HIV/
AIDS, Vancouver, Canada;; 4 Univ of Oxford, UK;; and 5 Simon Fraser
Univ, Burnaby, Canada
c Monday, 2:30-4 pm; Hall B2
Session 64–Poster Abstracts
HIV Compartments
242
Andy Chevigne* 1 , V Fievez1 , S Delhalle1 , M Counson1 , J-M Plesseria1 ,
C Devaux1 , J-C Schmit1,2 , and S Deroo1 1 2 CRP-Sante, Luxembourg and Ctr Hosp de Luxembourg
243
on Magnetic Proteoliposomes
Virginie Fievez* 1 , S Deroo1 , S Delhalle1 , J Mathu1 , F Martin1 ,
C Devaux1 , J-C Schmit1,2 , and A Chevigne1 252
Matthieu Perreau*
1 2 CRP Sante, Luxembourg and CHL, Luxembourg
1,2 , A-L Savoye1,2 , E De Crignis1,2 , J-M Corpataux1,2 ,
R Cubas3 , E Haddad3 , L De Leval1 , C Graziosi1,2 , and G Pantaleo1,2,4 1 2 Lausanne Univ Hosp, Switzerland;; Univ of Lausanne, Switzerland;;
3 4 Vaccine and Gene Therapy Inst of Florida, Port St Lucie, US;; and Swiss
Vaccine Res Inst, Lausanne
253 Low-level HIV Plasma Viremia Is Rarely Due to Viral
Infected Cells During Systemic Inflammation
Marta Bull* 1,2 , C Mitchell1 , S Styrchak2 , J Soria3 , A LaRosa3 ,
E Ticona3 , J McKernan-Mullin2 , B Sorensen1 , R Coombs1 , and L Frenkel1,2 1 2 Univ of Washington, Seattle, US;; Seattle Childrens Res Inst, WA, US;;
and 3Assn Civil Impacta Salud y Educacion, Lima, Peru
Program 27
Poster Listings
254
Genital Tract
Elena Dukhovlinova* 1,2 , J Anderson1,3,4 , D Moore2 , M Cohen1,4 ,
R Swanstrom1,4 , and Ctr for HIV/AIDS Vaccine Immunology Consortium
1 2 Univ of North Carolina Ctr for AIDS Res;; Univ of North Carolina
Lineberger Comprehensive Cancer Ctr;; 3Bristol-Myers Squibb;; and 4Univ of North Carolina
255
M Surdo 1 , C Orlandi 2 , A Casabianca 2 , F Di Santo 1 , I Malet 3 ,
MF Cortese 1 , A-G Marcelin 3 , M Magnani 2 , C-F Perno 1,4 ,
and Francesca Ceccherini-Silberstein* 1
1 Univ of Rome Tor Vergata, Italy;; 2 Univ of Urbino Carlo Bo, Pesaro,
Italy;; 3 Groupe Hosp Pitie-Salpetriere, UPMC Univ Paris 06, France;;
and 4 INMI L Spallanzani, Rome, Italy
246
Kyle Nakamura* 1 , C Cerini1 , E Sobrera1 , L Heath2 , M Sinkala3 ,
C Kankasa4 , D Thea5 , J Mullins2 , L Kuhn6 , and G Aldrovandi1 1 2
Univ of Washington, Seattle, US;;
3 4 5 Lusaka District Hlth Mgmt Team, Zambia;; Univ of Zambia, Lusaka;; Boston
Univ Sch of Publ Hlth, MA, US;; and 6Columbia Univ, New York, NY, US
247
Differentially Utilize CCR5
Zahra Parker* 1 , S Iyer1 , C Wilen1 , N Parrish1 , R Berro2 , B Lee3 ,
J Moore2 , G Shaw1 , B Hahn1 , and R Doms1,4 1 2 Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US;; Weill
Med Coll of Cornell Univ, New York, NY, US;; 3Univ of California, Los
Angeles, US;; and 4 248
Throughput Receptor Affinity Profiling
Kelechi Chikere* 1 , N Webb1 , T Chou1 , P Gorry2 , and B Lee1 1 2 Univ of California, Los Angeles, US and Burnet Inst, Melbourne, Australia
249
Divergent SIVsmm Strains Are Infectious and Replication
Competent in vivo
D Ma1 , H Li2 , C Xu1 , B Keele3 , J Estes3 , J Lifson3 , I Pandrea1 , G Shaw2 ,
B Hahn2 , and Cristian Apetrei* 1
1 2 Ctr for Vaccine Res, Univ of Pittsburgh, PA, US;; Univ of Pennsylvania
Perelman Sch of Med, Philadelphia, US;; and 3Frederick Natl Lab, MD, US
250
Virus Impact Clinical Outcome in Vaginal R5 SHIV Transmission
Lily Tsai* 1 , I Tasovski2 , AR Leda1 , M Chin2 , and C Cheng-Mayer1 256 Evidence of Long-term Persistence of Human Effector
1 2 Aaron Diamond AIDS Res Ctr, New York, NY, US and Temple Univ Sch
of Med, Philadelphia, PA, US
+ T Cells Using Replication-defective Integrated
HIV-1 Provirus as a Genetic Marker
Hiromi Imamichi* 1 , V Natarajan2 , T Imamichi2 , J Adelsberger2 ,
C Rehm1 , and C Lane1 1 2 NIAID, NIH, Bethesda, MD, US and SAIC-Frederick Inc, MD, US
c Wednesday, 2:30-4 pm; Hall B2
Session 65–Poster Abstracts
HIV Genotypes and Phenotypes
257
in HIV-1 Seroconverters from Different Risk Groups
R McGovern1 , Z Brumme1,2 , C Johnson1 , R Hogg1,2 , E Wood1,3 , T Kerr1,3 ,
M Milloy1 , R Harrigan1,3 , Art Poon* 1,3 , and VANGUARD and
VIDUS/ACCESS Cohort Studies
1 2 BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada;; Simon Fraser
Univ, Burnaby, Canada;; and 3Univ of British Columbia, Vancouver,
Canada
258a
with MTCT
Li Yin* 1 , Y Cai1 , N Veras1 , K Chang1 , B Gardner1 , W Hou1 ,
K Nakamura2 , L Kuhn3 , G Aldrovandi2 , and M Goodenow1 1 2 Univ of Florida, Gainesville, US;;
Los Angeles, CA, US;; and 3Columbia Univ, New York, NY, US
258b
Viral Load
Emma Hodcroft* 1 , E Fearnhill2 , A Phillips3 , D Dunn2 , D Pillay4 ,
J Hadfield5, A Leigh Brown1 , and UK HIV Drug Resistance Database
1 2 Univ of Edinburgh, Scotland;; MRC Clin Trials Unit, London, UK;;
3 4 5 Royal Free Hosp, London, UK;; Univ Coll London, UK;; and Univ of
Oxford, UK
259
Martha Lewis* 1 , J de la Cruz1 , P Frohnen1 , H Ng1 , E Daar2 , and O Yang1 1 2 David Geffen Sch of Med, Univ of California, Los Angeles, US and LA
BioMed, Harbor UCLA Med Ctr, US
260
Become Viremic Controllers
Xiaomei Kuang* 1 , A Le 1 , P Mwimanzi 1 , T Markle 1 , R Danroth 1 ,
T Ueno 2 , T Miura 3 , B Walker 4 , Z Brumme 1,5 , M Brockman 1,5 ,
and Acute HIV and Intl HIV Controllers Study Group
1 Simon Fraser Univ, Vancouver, Canada;; 2 Kumamoto Univ, Japan;; 3 Univ
of Nagasaki, Japan;; 4 Ragon Inst of MGH, MIT, and Harvard, Boston,
MA, US;; and 5 BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada